New Contrast Agent Enables Low-Dose X-Ray Joint Imaging

X-ray imaging offers limited visualization of soft tissues like cartilage, complicating evaluation of joint pain and degenerative disease. Clinicians often rely on joint-space narrowing as a proxy for cartilage loss, which can be imprecise. Iodine-based contrast agents help but require larger volumes and may pose risks for patients with kidney disease. To help address this challenge, researchers have developed a positively charged contrast agent designed to improve X‑ray visualization of cartilage.

Developed at Northeastern University under the leadership of Ambika Bajpayee, an associate professor of bioengineering, the agent is engineered to leverage the inherent negative charge of soft tissues. The team recently secured a patent for its cationic design, which targets cartilage through electrostatic attraction. By binding to the tissue rather than diffusing away, the agent is designed to improve retention at the site of interest and enable clearer assessment of joint structures using standard radiography.

Image: Ambika Bajpayee and her team at Northeastern developed a patented contrast agent 100 times more efficient than current options (photo courtesy of Ruby Wallau/Northeastern University)

Soft tissues carry net negative charges due to molecules such as proteins and cell membranes. In cartilage, fixed negative charges also contribute substantially to mechanical properties, supporting restoration of shape after load-bearing. A positively charged contrast agent is drawn into these tissues, where it accumulates and remains available for X‑ray detection more effectively than conventional agents.

The approach aims to address two clinical limitations of current arthrography: poor retention in cartilage because of low perfusion and the need for relatively high injected volumes. According to the developers, imaging with the new method can be performed using approximately 40 times less contrast than usual. The injected agent is absorbed into the joint over about two hours, and it is expected to break down in the body after roughly 24 hours, although additional testing is needed.

Initial studies were conducted in mice, and evaluation in human subjects is anticipated next. If validated clinically, the method could refine radiographic assessment of arthritis by directly enhancing visualization of cartilage rather than relying solely on joint-space measurements.

Related Links
Northeastern University